{"rows":[{"id":5908,"title":"A response to the letter to editor: Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy.","authors":"Khan FA, Pandupuspitasari NS, Tencomnao T, Chuchawankul S.","journal":"Journal of affective disorders","publication_date":"2026-09-02","publication_year":2026,"doi":"10.1016/j.jad.2026.122450","pubmed_id":"42686072","openalex_id":null,"source_url":"https://doi.org/10.1016/j.jad.2026.122450","substance_tags":"psilocybin","topic_tags":"Depression,Meta-Analysis,Systematic Review,Review Article","study_type":"Meta-Analysis","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-04 01:20:05","last_checked":"2026-09-09 01:20:55","bibtex":null,"source_record_id":"PMID:42686072","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42686072","source_url":"https://doi.org/10.1016/j.jad.2026.122450","doi":"10.1016/j.jad.2026.122450","pmid":"42686072","publication_date":"2026-09-02","importer_version":"2.1.3","text_redistributed":false}},{"id":5779,"title":"Correspondence: \"Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy\".","authors":"Hörnqvist N.","journal":"Journal of affective disorders","publication_date":"2026-08-06","publication_year":2026,"doi":"10.1016/j.jad.2026.122315","pubmed_id":"42562064","openalex_id":null,"source_url":"https://doi.org/10.1016/j.jad.2026.122315","substance_tags":"psilocybin","topic_tags":"Depression,Meta-Analysis,Systematic Review,Review Article","study_type":"Meta-Analysis","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-07 01:20:13","last_checked":"2026-08-13 01:20:23","bibtex":null,"source_record_id":"PMID:42562064","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42562064","source_url":"https://doi.org/10.1016/j.jad.2026.122315","doi":"10.1016/j.jad.2026.122315","pmid":"42562064","publication_date":"2026-08-06","importer_version":"2.1.3","text_redistributed":false}},{"id":2416,"title":"Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.","authors":"Carrillo F, Sigman M, Fernández Slezak D, Ashton P, Fitzgerald L, Stroud J, Nutt DJ, Carhart-Harris RL","journal":"Journal of affective disorders","publication_date":"2018-04-01","publication_year":2018,"doi":"10.1016/j.jad.2018.01.006","pubmed_id":"29407543","openalex_id":"https://openalex.org/W2790056169","source_url":"https://pubmed.ncbi.nlm.nih.gov/29407543/","substance_tags":"psilocybin","topic_tags":"Depression,Treatment-Resistant Depression","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:26","bibtex":null,"source_record_id":"PMID:29407543","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/29407543/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:29407543","source_url":"https://pubmed.ncbi.nlm.nih.gov/29407543/","doi":"10.1016/j.jad.2018.01.006","pmid":"29407543","publication_date":"2018-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2320,"title":"Classical psychedelics for the treatment of depression and anxiety: A systematic review.","authors":"Muttoni S, Ardissino M, John C","journal":"Journal of affective disorders","publication_date":"2019-11-01","publication_year":2019,"doi":"10.1016/j.jad.2019.07.076","pubmed_id":"31382100","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/31382100/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,End-of-Life Distress,Headache / Migraine,Clinical Trial,Systematic Review,Review Article,Safety","study_type":"Systematic Review","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:25","bibtex":null,"source_record_id":"PMID:31382100","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/31382100/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:31382100","source_url":"https://pubmed.ncbi.nlm.nih.gov/31382100/","doi":"10.1016/j.jad.2019.07.076","pmid":"31382100","publication_date":"2019-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2291,"title":"The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.","authors":"Mathai DS, Meyer MJ, Storch EA, Kosten TR","journal":"Journal of affective disorders","publication_date":"2020-03-01","publication_year":2020,"doi":"10.1016/j.jad.2019.12.023","pubmed_id":"32056741","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/32056741/","substance_tags":"psilocybin","topic_tags":"Depression,Mechanism of Action,Consciousness,Systematic Review,Review Article,Healthcare Workers","study_type":"Systematic Review","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:24","bibtex":null,"source_record_id":"PMID:32056741","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/32056741/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:32056741","source_url":"https://pubmed.ncbi.nlm.nih.gov/32056741/","doi":"10.1016/j.jad.2019.12.023","pmid":"32056741","publication_date":"2020-03-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1863,"title":"Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.","authors":"Li NX, Hu YR, Chen WN, Zhang B","journal":"Journal of affective disorders","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1016/j.jad.2021.09.041","pubmed_id":"34587546","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/34587546/","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Meta-Analysis,Systematic Review,Review Article,Cancer Patients","study_type":"Meta-Analysis","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:21","bibtex":null,"source_record_id":"PMID:34587546","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/34587546/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:34587546","source_url":"https://pubmed.ncbi.nlm.nih.gov/34587546/","doi":"10.1016/j.jad.2021.09.041","pmid":"34587546","publication_date":"2022-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1572,"title":"Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.","authors":"Ko K, Kopra EI, Cleare AJ, Rucker JJ","journal":"Journal of affective disorders","publication_date":"2023-02-01","publication_year":2023,"doi":"10.1016/j.jad.2022.09.168","pubmed_id":"36209780","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/36209780/","substance_tags":"psilocybin","topic_tags":"Depression,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:17","bibtex":null,"source_record_id":"PMID:36209780","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36209780/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36209780","source_url":"https://pubmed.ncbi.nlm.nih.gov/36209780/","doi":"10.1016/j.jad.2022.09.168","pmid":"36209780","publication_date":"2023-02-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1558,"title":"Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.","authors":"Shnayder S, Ameli R, Sinaii N, Berger A, Agrawal M","journal":"Journal of affective disorders","publication_date":"2023-02-15","publication_year":2023,"doi":"10.1016/j.jad.2022.11.046","pubmed_id":"36513161","openalex_id":"https://openalex.org/W4312196530","source_url":"https://pubmed.ncbi.nlm.nih.gov/36513161/","substance_tags":"psilocybin","topic_tags":"Depression,Wellbeing,Spirituality,Clinical Trial,Cancer Patients","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:17","bibtex":null,"source_record_id":"PMID:36513161","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36513161/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36513161","source_url":"https://pubmed.ncbi.nlm.nih.gov/36513161/","doi":"10.1016/j.jad.2022.11.046","pmid":"36513161","publication_date":"2023-02-15","importer_version":"2.1.3","text_redistributed":false}},{"id":1557,"title":"Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.","authors":"Meir P, Taylor L, Soares JC, Meyer TD","journal":"Journal of affective disorders","publication_date":"2023-02-15","publication_year":2023,"doi":"10.1016/j.jad.2022.12.050","pubmed_id":"36535547","openalex_id":"https://openalex.org/W4312084004","source_url":"https://pubmed.ncbi.nlm.nih.gov/36535547/","substance_tags":"psilocybin","topic_tags":"Healthcare Workers,Safety","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:17","bibtex":null,"source_record_id":"PMID:36535547","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36535547/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36535547","source_url":"https://pubmed.ncbi.nlm.nih.gov/36535547/","doi":"10.1016/j.jad.2022.12.050","pmid":"36535547","publication_date":"2023-02-15","importer_version":"2.1.3","text_redistributed":false}},{"id":1513,"title":"Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.","authors":"Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-Jones M, Schlosser D, Aaronson ST","journal":"Journal of affective disorders","publication_date":"2023-04-01","publication_year":2023,"doi":"10.1016/j.jad.2023.01.077","pubmed_id":"36707036","openalex_id":"https://openalex.org/W4318393298","source_url":"https://pubmed.ncbi.nlm.nih.gov/36707036/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,OCD,End-of-Life Distress,Safety","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:16","bibtex":null,"source_record_id":"PMID:36707036","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36707036/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36707036","source_url":"https://pubmed.ncbi.nlm.nih.gov/36707036/","doi":"10.1016/j.jad.2023.01.077","pmid":"36707036","publication_date":"2023-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1512,"title":"Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.","authors":"Simonsson O, Hendricks PS, Chambers R, Osika W, Goldberg SB","journal":"Journal of affective disorders","publication_date":"2023-04-01","publication_year":2023,"doi":"10.1016/j.jad.2023.01.073","pubmed_id":"36720405","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/36720405/","substance_tags":"psilocybin","topic_tags":"Safety","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:16","bibtex":null,"source_record_id":"PMID:36720405","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36720405/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36720405","source_url":"https://pubmed.ncbi.nlm.nih.gov/36720405/","doi":"10.1016/j.jad.2023.01.073","pmid":"36720405","publication_date":"2023-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1502,"title":"Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.","authors":"Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E","journal":"Journal of affective disorders","publication_date":"2023-04-14","publication_year":2023,"doi":"10.1016/j.jad.2023.01.108","pubmed_id":"36740140","openalex_id":"https://openalex.org/W4319067008","source_url":"https://pubmed.ncbi.nlm.nih.gov/36740140/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:16","bibtex":null,"source_record_id":"PMID:36740140","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36740140/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36740140","source_url":"https://pubmed.ncbi.nlm.nih.gov/36740140/","doi":"10.1016/j.jad.2023.01.108","pmid":"36740140","publication_date":"2023-04-14","importer_version":"2.1.3","text_redistributed":false}},{"id":1497,"title":"Unblinding and demand characteristics in the treatment of depression.","authors":"Goodwin GM, Croal M, Marwood L, Malievskaia E","journal":"Journal of affective disorders","publication_date":"2023-05-01","publication_year":2023,"doi":"10.1016/j.jad.2023.02.030","pubmed_id":"36781142","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/36781142/","substance_tags":"psilocybin","topic_tags":"Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:16","bibtex":null,"source_record_id":"PMID:36781142","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36781142/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36781142","source_url":"https://pubmed.ncbi.nlm.nih.gov/36781142/","doi":"10.1016/j.jad.2023.02.030","pmid":"36781142","publication_date":"2023-05-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1451,"title":"The need for establishing best practices and gold standards in psychedelic medicine.","authors":"Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM","journal":"Journal of affective disorders","publication_date":"2023-07-01","publication_year":2023,"doi":"10.1016/j.jad.2023.03.083","pubmed_id":"37003433","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/37003433/","substance_tags":"psilocybin","topic_tags":"Depression,PTSD,Clinical Trial,Review Article,Safety","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:15","bibtex":null,"source_record_id":"PMID:37003433","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/37003433/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:37003433","source_url":"https://pubmed.ncbi.nlm.nih.gov/37003433/","doi":"10.1016/j.jad.2023.03.083","pmid":"37003433","publication_date":"2023-07-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1422,"title":"How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.","authors":"Zeifman RJ, Wagner AC, Monson CM, Carhart-Harris RL","journal":"Journal of affective disorders","publication_date":"2023-08-01","publication_year":2023,"doi":"10.1016/j.jad.2023.04.105","pubmed_id":"37146908","openalex_id":"https://openalex.org/W4367840575","source_url":"https://pubmed.ncbi.nlm.nih.gov/37146908/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Wellbeing,Randomized Controlled Trial","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:14","bibtex":null,"source_record_id":"PMID:37146908","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/37146908/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:37146908","source_url":"https://pubmed.ncbi.nlm.nih.gov/37146908/","doi":"10.1016/j.jad.2023.04.105","pmid":"37146908","publication_date":"2023-08-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1366,"title":"Letter to the editor on \"Increased low-frequency brain responses to music after psilocybin therapy for depression\".","authors":"Brown O","journal":"Journal of affective disorders","publication_date":"2023-10-01","publication_year":2023,"doi":"10.1016/j.jad.2023.05.088","pubmed_id":"37257781","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/37257781/","substance_tags":"psilocybin","topic_tags":"Depression","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:12","bibtex":null,"source_record_id":"PMID:37257781","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/37257781/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:37257781","source_url":"https://pubmed.ncbi.nlm.nih.gov/37257781/","doi":"10.1016/j.jad.2023.05.088","pmid":"37257781","publication_date":"2023-10-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1177,"title":"A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.","authors":"Wong S, Kwan ATH, Teopiz KM, Le GH, Meshkat S, Ho R, d'Andrea G, Cao B, Di Vincenzo JD, Rosenblat JD, McIntyre RS","journal":"Journal of affective disorders","publication_date":"2024-04-01","publication_year":2024,"doi":"10.1016/j.jad.2024.01.142","pubmed_id":"38244804","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/38244804/","substance_tags":"psilocybin","topic_tags":"Depression,Headache / Migraine,Randomized Controlled Trial,Systematic Review,Review Article,Treatment-Resistant Depression","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:09","bibtex":null,"source_record_id":"PMID:38244804","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/38244804/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:38244804","source_url":"https://pubmed.ncbi.nlm.nih.gov/38244804/","doi":"10.1016/j.jad.2024.01.142","pmid":"38244804","publication_date":"2024-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1135,"title":"Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.","authors":"Copa D, Erritzoe D, Giribaldi B, Nutt D, Carhart-Harris R, Tagliazucchi E","journal":"Journal of affective disorders","publication_date":"2024-05-15","publication_year":2024,"doi":"10.1016/j.jad.2024.02.089","pubmed_id":"38423367","openalex_id":"https://openalex.org/W4392203910","source_url":"https://pubmed.ncbi.nlm.nih.gov/38423367/","substance_tags":"psilocybin","topic_tags":"Depression,Brain Imaging,Aging,Treatment-Resistant Depression","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:09","bibtex":null,"source_record_id":"PMID:38423367","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/38423367/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:38423367","source_url":"https://pubmed.ncbi.nlm.nih.gov/38423367/","doi":"10.1016/j.jad.2024.02.089","pmid":"38423367","publication_date":"2024-05-15","importer_version":"2.1.3","text_redistributed":false}},{"id":1108,"title":"Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.","authors":"Le GH, Wong S, Badulescu S, Au H, Di Vincenzo JD, Gill H, Phan L, Rhee TG, Ho R, Teopiz KM, Kwan ATH, Rosenblat JD, Mansur RB, McIntyre RS","journal":"Journal of affective disorders","publication_date":"2024-06-15","publication_year":2024,"doi":"10.1016/j.jad.2024.03.165","pubmed_id":"38570038","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/38570038/","substance_tags":"psilocybin","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Biomarkers,Systematic Review,Review Article,Healthy Volunteers,Treatment-Resistant Depression","study_type":"Systematic Review","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:08","bibtex":null,"source_record_id":"PMID:38570038","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/38570038/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:38570038","source_url":"https://pubmed.ncbi.nlm.nih.gov/38570038/","doi":"10.1016/j.jad.2024.03.165","pmid":"38570038","publication_date":"2024-06-15","importer_version":"2.1.3","text_redistributed":false}},{"id":859,"title":"Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.","authors":"Ellis S, Bostian C, Feng W, Fischer E, Schwartz G, Eisen K, Lean M, Conlan E, Ostacher M, Aaronson S, Suppes T","journal":"Journal of affective disorders","publication_date":"2025-01-15","publication_year":2025,"doi":"10.1016/j.jad.2024.09.133","pubmed_id":"39343309","openalex_id":"https://openalex.org/W4402912774","source_url":"https://pubmed.ncbi.nlm.nih.gov/39343309/","substance_tags":"psilocybin","topic_tags":"Depression,PTSD,Consciousness,Treatment-Resistant Depression,Veterans,Safety,Adverse Events,Drug Interactions","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:04","last_checked":"2026-08-09 08:28:04","bibtex":null,"source_record_id":"PMID:39343309","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/39343309/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:39343309","source_url":"https://pubmed.ncbi.nlm.nih.gov/39343309/","doi":"10.1016/j.jad.2024.09.133","pmid":"39343309","publication_date":"2025-01-15","importer_version":"2.1.3","text_redistributed":false}}],"total":33,"page":1,"per_page":20,"pages":2,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"Journal of affective disorders","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}